Ghana FDA Pharmaceutical Import: A 2026 Guide for UK Exporters

Ghana is one of the more developed pharmaceutical markets in West Africa. It has an active domestic manufacturing sector, a regulator widely respected across the region, and a hospital network that relies on imported specialty and originator medicines for cases its local supply cannot cover. For a hospital pharmacist in Accra, a Ministry of Health procurement officer, an NGO running a public health programme, or a licensed Ghanaian distributor, the practical question is usually the same: how do you bring in a UK-licensed medicine in a way the regulator will accept, on a timeline that works for the patient.

That entire process runs through one body: the Food and Drugs Authority, the FDA. This guide explains how the FDA works, the routes a UK-licensed medicine can take into Ghana, the documentation involved, and how supply from an MHRA-licensed UK wholesale exporter fits the pathway in 2026. It is written for the buyer side, not for regulatory consultants.

One point to set out plainly at the start. Euro Biom is a UK MHRA-licensed wholesale exporter. We supply UK-licensed, MHRA-authorised finished medicines. We do not manufacture, and we are not a regulatory consultancy. Where this guide describes registration mechanics, those are the buyer's and local agent's responsibilities in Ghana. Our role is the UK supply leg, explained towards the end.

What the FDA Is and What It Controls

Ghana's Food and Drugs Authority is the national regulatory authority for medicines, medical devices, food, cosmetics and household chemicals. Within the pharmaceutical remit it is responsible for marketing authorisation (commonly called registration), import permits and port-of-entry inspection, Good Manufacturing Practice expectations, market surveillance and quality control, pharmacovigilance, and advertising control.

Several features matter for a UK exporter and a Ghanaian buyer:

• It is a mature regulator. The FDA is assessed at maturity level 3 under the WHO Global Benchmarking Tool, among the more capable authorities on the continent, and participates in WHO prequalification and collaborative review rather than working in isolation.
• It tests product, not just paper. The FDA operates laboratory quality control and commonly requires samples for analysis, depending on the application and dosage form. This is a recognised strength of the Ghanaian system and a reason its approvals carry weight in the sub-region.
• It controls the consignment, not only the product. Registration authorises a product, but a separate import permit and port inspection control each consignment. Both layers must be satisfied for goods to clear.

For the country-level overview of how Euro Biom supplies this market, see our UK pharmaceutical supplier to Ghana page, and for how Ghana sits alongside neighbouring regulators see the regulator comparison tool.

Routes into the Ghanaian Market

A UK-licensed medicine generally reaches a Ghanaian hospital or patient by one of two broad routes. Choosing correctly at the outset saves months.

1. Full FDA registration

This is the route for any product supplied routinely and at volume. The foreign manufacturer or product owner, represented by a Ghanaian local agent (a registered pharmaceutical wholesale company or accredited manufacturer's representative), submits a registration dossier to the FDA. The FDA reviews the quality, safety and efficacy documentation, may require samples for laboratory analysis, and grants a marketing authorisation. Registration is what allows a product to be tendered, stocked and dispensed across the market on an ongoing basis, imported under the importer's FDA permit.

2. Special import for an unregistered or unavailable medicine (named-patient route)

Where a medicine is not registered in Ghana, or is registered but not currently available, it can still be brought in with prior FDA approval supported by clinical justification. This is the route most relevant to specialty, oncology and rare-disease cases where no registered local equivalent exists. Importantly, this is the buyer's in-country mechanism for importing a product that already holds a marketing authorisation somewhere else, for example a UK-licensed medicine. It is not a route for supplying an unlicensed product. The medicine itself is a properly authorised UK product; the special-import approval is simply the Ghanaian regulatory permission to bring that authorised product in for a defined clinical need.

Prior approval is obtained before the product is imported, supported by clinical documentation that establishes the need, typically a prescription or supporting letter from a practitioner licensed in Ghana, with quantities aligned to the clinical need. Our named patient supply service describes how the UK side of this is handled.

Documentation the FDA Expects

For a full registration, the FDA dossier is supported by a set of country-of-origin certificates and product documentation. The table below sets out the core documents a UK-licensed product will typically need, and who issues each one.

Two practical points sit behind that table. First, legalisation: certificates issued in the country of origin generally have to be authenticated or legalised through the issuing authority and consular route before the FDA accepts them. Build this in early, because legalisation queues are a common and avoidable source of delay.

Second, the CPP is the document buyers underestimate. For a foreign-manufactured product the FDA wants confirmation that the medicine is genuinely licensed in its country of origin, and the CPP issued by the MHRA under the WHO certification scheme is the cleanest way to give them that. MHRA CPPs take time to obtain, so request them well ahead of a submission window. For the wider UK-side picture, see our guide to UK pharmaceutical import documentation.

The Import Permit and Port of Entry

Registration and importation are two distinct controls in Ghana, and the second is easy to overlook. Even where a product is registered, the importer or local agent must be registered with the FDA and hold a valid import permit for the consignment. In practice this is handled through Ghana's Integrated Customs Management System, with the FDA permit sitting alongside customs clearance.

Imported medicines are then inspected at the authorised ports of entry, for example the airport at Accra or the seaport at Tema. The inspection checks that what arrives matches the permit and the authorised particulars, and that the consignment is in good condition. For a UK supplier the takeaway is simple: the export pack must line up exactly with the permit the buyer holds, because mismatches between paperwork and goods are a frequent cause of hold-ups at the port.

How UK-Licensed Supply Fits the FDA Pathway

There is a structural reason UK-licensed product travels well into Ghana. The FDA wants assurance that a medicine is properly authorised, manufactured to GMP, and traceable batch by batch. A UK-licensed, MHRA-authorised finished medicine arrives with exactly that evidence in place: a marketing authorisation, a manufacturer under MHRA GMP oversight, a CPP available from the MHRA, and Qualified Person batch release with a Certificate of Analysis per batch.

Because the FDA recognises stringent-authority documentation and works within WHO frameworks, the UK paperwork does not have to be reconstructed for the Ghanaian system, it has to be assembled, legalised and presented. That is the difference between a smooth submission and a stalled one, and it is largely an execution problem rather than a regulatory one.

It is worth being precise about what UK-licensed supply means here. It means finished medicines that hold a UK marketing authorisation and are released to the UK market. It does not mean unlicensed specials, and across every route, full registration or special import, the product Euro Biom supplies is a UK-licensed, MHRA-authorised medicine. The named-patient or special-import permission is a feature of the Ghanaian buyer's import route, not a change in the licensed status of the product itself.

Cold Chain and GDP for the Ghana Lane

Many of the specialty medicines that move from the UK to Ghana are temperature sensitive. Where that is the case, Good Distribution Practice and validated cold chain keep the consignment compliant and the product usable on arrival. The controls that matter on this lane are:

• Validated temperature-controlled storage in the UK at the labelled storage condition before despatch.
• Qualified shipping containers suited to the warm, humid ambient profile expected on the journey to Accra.
• Continuous temperature monitoring with a calibrated data logger, so the history can be reviewed on arrival and at port inspection.
• A GDP-compliant transport chain from the UK warehouse to the Ghanaian importer, with a documented procedure for any temperature excursion.

Heathrow proximity makes the UK an efficient origin for this lane, with direct air links to Accra and short despatch times for urgent or shortage cases. For the mechanics, see our UK cold chain pharmaceutical supply page and the pharma cold chain logistics guide.

Common Pitfalls and How to Avoid Them

The same handful of issues account for most delays on Ghana-bound supply. Each is straightforward to design out at the start.

1. Treating legalisation as an afterthought

Certificates that are not properly authenticated or legalised will not be accepted. This is procedural rather than scientific, but it stops a submission cold. Map the legalisation chain for every certificate before you start.

2. An out-of-date or wrong-format CPP

The CPP must confirm the UK-licensed status of the specific product and site, and it has a shelf life of its own. Request it early and check it names the correct manufacturing site and approved particulars.

3. Forgetting that the permit is a separate step

Registration does not by itself clear a consignment. The importer must hold a valid FDA import permit and the goods must pass port inspection. Confirm the permit is in place and matches the shipment before despatch.

4. Confusing the two routes

Pushing an individual patient case through full registration, or treating a special-import approval as a substitute for registration in routine supply, both waste time. Match the route to the clinical and commercial reality up front.

5. Cold chain without a deviation procedure

A validated shipment can still see an excursion. Without an agreed deviation-handling procedure between supplier and consignee, an excursion can leave a consignment in limbo, or fail at port inspection. Agree it before the first shipment.

6. Leaving the local agent decision to last

The Ghanaian local agent is central to the whole process, from dossier submission to permits and port clearance. Their standing and systems materially affect speed. This is not a box to tick cheaply at the end.

How Euro Biom Supports Buyers in Ghana

Euro Biom is a UK MHRA-licensed pharmaceutical wholesale exporter, holding Wholesale Dealer Authorisation WDA(H) 59239. We supply UK-licensed, MHRA-authorised finished medicines and operate the UK leg of an FDA-compliant import, working with hospital pharmacies, Ministry of Health buyers, NGOs and licensed Ghanaian distributors and their local agents. Across the FDA pathway, our role typically covers:

• UK-side documentation. Coordinating the MHRA CPP and GMP evidence, and assembling the GDP export pack: batch release certificate, Certificate of Analysis, packing list and commercial invoice.
• Named-patient and special-import supply. Supplying the UK-licensed product with the country-of-origin documentation the Ghanaian importer needs to support an FDA special-import application.
• Cold-chain logistics. GDP-validated storage, qualified containers, calibrated data loggers, and despatch from near Heathrow to Accra.
• Shortage and urgent supply. Rapid response on UK-licensed lines where Heathrow proximity and same-week despatch are decisive.

See our UK pharmaceutical supplier to Ghana page, the import documentation guide, and our services overview.